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Background/Purpose: The nuclear oncoprotein
DEK is a biochemically distinct protein, modulating
heterochromatin integrity, chemoattractant of neutro-
phils and T-cells and vital for the formation of neutro-
phil extracellular traps (NETs). NETs are important for
resolution of inflammation suggesting that DEK contrib-
utes to the development of autoimmune diseases. High
levels of DEK autoantibodies have been found in several
autoimmune diseases including juvenile idiopathic ar-
thritis (JIA) but their role in disease pathogenesis is
not clear. Since DEK and DEK autoantibodies can
contribute to the development of immune complexes
and NET formation we suggest that DEK antibody
levels can predict flare with the discontinuation of
anti-TNF therapy.
Methods: In16 pediatric rheumatology centers,
sera samples were collected from 137 children with
polyarticular JIA with clinically inactive disease (CID)
on anti-TNF therapy. The therapy was stopped and
disease activity was monitored for at least 8 months or
until disease flare. DEK antibody levels were measured
in sera collected at time of enrollment and 6 months
(when anti-TNF therapy was stopped) by ELISA. DEK
antibody levels relative to healthy controls were calcu-
lated by area under the curve (AUC), expressed as
unit-free ratios.
Results: 103 females and 34 males patients were
enrolled. Mean age 11.3 years and disease duration 5.0
years. JIA included: 13% extended oligoarthritis, 74%
polyarthritis rheumatoid factor (RF) negative and 12 %
polyarthritis RF positive and 46% positive ANA. 77%
were taking etanercept, 18% adalimumab, 5% infliximab
and 40% methotrexate. 31 patients (23%) discontinued
the study prior stopping the therapy for various reasons,
including loss of CID. Of 106 subjects who stopped the
therapy, 39 (37%) flared within 8 months (mean of 104.8
days). 67 subjects (63%) had no flares within 8 months
after stopping the therapy. 71 out of 106 patients sam-
ples were analyzed thus far for DEK antibody levels.
DEK antibody level ratios compared to healthy controls
was0.36 (some patients had lower antibody levels than
did healthy controls) to 1.41, median ratio of 0.11
(Q1–Q3 of 0.09–0.24) and 0.13 (SD, 0.3). High levels of
DEK antibodies, mean and SD of 0.209  0.36 were
detected in the 21 patients that flared within 8 months
compared to lower levels of DEK antibodies (0.09 
0.27) in 50 patients with CID for at least 8 months
(ANOVA P 0.1832). Negative correlation was ob-
served between the days to flare and DEK antibody
levels (spearman rho0.31, P 0.07), suggesting that
when therapy stopped, patients with higher levels of
DEK antibodies will flare sooner with estimated odds
ratio of 3.3 (95% CI, 0.61, 18.0), suggesting that each
unit increase in DEK antibodies is associated (P  0.17)
with more than a 2-fold increased risk of flare within 8
months.
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Conclusion: In children with JIA extended oligo-
arthritis and polyarthritis on anti-TNF therapy that
maintain CID for at least 6 months while on therapy,
high DEK antibody levels may be correlated with flare
within the first 8 months after stopping the therapy. This
study suggests that DEK antibody levels can predict the
outcome of discontinuation of anti-TNF therapy, al-
though more patient samples need to be analyzed from
this study and future studies.
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